Minerva Neurosciences reported $0 in Loan Capital for its fiscal quarter ending in September of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Adma Biologics USD 191.64M 1.2M Sep/2026
ALKERMES USD 1.47B 5.38M Sep/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
AstraZeneca USD 28.8B 2.79B Sep/2026
BioCryst Pharmaceuticals USD 395.61M 209K Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Cipla INR 4.69B 874.1M Sep/2026
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 46.99B 872M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Grifols EUR 9.95B 722.93M Dec/2025
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
J&J USD 35.8B 1.55B Sep/2026
Merck USD 49.69B 1.39B Sep/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60B 498M Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 16.28B 1.63B Sep/2026
Takeda JPY 4.17T 245.32B Sep/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024